<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T05:41:12Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/10718" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/10718</identifier><datestamp>2026-09-24T06:22:51Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Berti, Paul</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Giuseppe Melacini, Murray Junop</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Giuseppe Melacini, Murray Junop</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Jiang, Shan</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Chemical Biology</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T16:52:22Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T16:52:22Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2011-07-27</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2011-10</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/5746</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">6627</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">2119320</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/10718</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/18487</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>MurA catalyzes the first committed step of peptidoglycan biosynthesis and it is the target of the antibiotic fosfomycin. Due to a Cys-to-Asp substitution in the active site, MurAs from a number of pathogenic bacteria, including &lt;em>Mycobacterium tuberculosis&lt;/em> and &lt;em>Borrelia burgdorferi&lt;/em> (Lyme disease), are fosfomycin resistant. His-tagged &lt;em>Borrelia burgdorferi&lt;/em> MurA (Bb_MurA) and its D116C mutant have been successfully expressed, purified and characterized. The &lt;em>k&lt;/em>&lt;sub>cat&lt;/sub> value of wild-type Bb_MurA was 0.74 ± 0.01 s&lt;sup>-1&lt;/sup>. The D116C mutant’s &lt;em>k&lt;/em>&lt;sub>cat&lt;/sub> decreased by 25-fold and was fosfomycin sensitive. The pH profiles of &lt;em>k&lt;/em>&lt;sub>cat&lt;/sub> for both Bb_MurA and its mutant were characterized. There was little difference in p&lt;em>K&lt;/em>&lt;sub>a1&lt;/sub> values, but the p&lt;em>K&lt;/em>&lt;sub>a2&lt;/sub> value shifted from 7.4 ± 0.2 in wild-type enzyme to a value >11 in the mutant. This demonstrated that the p&lt;em>K&lt;/em>&lt;sub>a2&lt;/sub> of 7.4 was due to D116, and that it must be protonated for activity. Fosfomycin inactivation of Bb_MurA&lt;sub>H6&lt;/sub>(D116C) was time-dependent and only proceeded in the presence of UDP-GlcNAc. The dissociation constant, &lt;em>K&lt;/em>&lt;sub>i&lt;/sub>, was 5.7 ± 0.4 µM and rate of covalent modification, &lt;em>k&lt;/em>&lt;sub>inact&lt;/sub>, was 0.021 ± 0.003 s&lt;sup>-1&lt;/sup>.&lt;/p> &lt;p>DAHP synthase catalyzes the first committed step in the shikimate pathway, and its catalysis has been proposed to proceed through two oxacarbenium ion intermediates. Pyruvate oxime, glyoxylate oxime and 4-imidazolecarboxylic acid have been evaluated as inhibitors of DAHP synthase. In the presence of glycerol 3-phosphate, the fitted &lt;em>K&lt;/em>&lt;sub>i&lt;/sub> values of pyruvate oxime and glyoxylate oxime were 7.6 (± 0.9) × 10&lt;sup>-5&lt;/sup> M and 7.4 (± 1.7) × 10&lt;sup>-5&lt;/sup> M, respectively. 4-Imidazolecarboxylic acid’s inhibition was cooperative, and its binding was competitive with respect to PEP, and uncompetitive with respect to E4P. Its equilibrium dissociation constant was 3.0 (± 0.2) × 10&lt;sup>-3&lt;/sup> M.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Asp-containing MurA</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">pH profile characterization</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">fosfomycin titration</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">fragment-based approach</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">transition state analog design</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Biochemistry</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Biochemistry</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Characterization of Fosfomycin-Resistant MurA from Borrelia burgdorferi, Fragment-based Inhibitor Design for AroA and DAHP Synthase</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>